Filtered By:
Condition: Crohn's Disease
This page shows you your search results in order of date.
Order by Relevance | Date
Total 50 results found since Jan 2013.
Atherosclerosis as a Risk Factor for IBD: A Population-Based Case-Control Study
CONCLUSIONS: A history of an atherosclerotic-related condition is associated with increased odds of developing IBD, particularly among older adults. Future studies should investigate whether drugs targeting atherosclerotic-related inflammation may prevent IBD in higher-risk individuals.PMID:37721310 | DOI:10.14309/ajg.0000000000002502
Source: Atherosclerosis - September 18, 2023 Category: Cardiology Authors: Adam S Faye Jordan Axelrad Jiangwei Sun Jonas Halfvarson Jonas S öderling Ola Ol én Jonas F Ludvigsson Source Type: research
Inflammatory bowel disease and cardiovascular diseases
Inflammatory Bowel Disease is comprised of two major subtypes: Crohn's disease and ulcerative colitis, characterized by chronic inflammation of the gastrointestinal tract with extraintestinal manifestations that can involve a number of systems.1 There were estimated to be 7 million cases of inflammatory bowel disease globally in 2017, and at the national level, the United States had the highest age-standardized prevalence rate (464.5 per 100,000 population) of inflammatory bowel disease.2 Atherosclerotic cardiovascular diseases is defined as a history of acute coronary syndrome, myocardial infarction, stable or unstable an...
Source: The American Journal of Medicine - September 1, 2022 Category: General Medicine Authors: Bing Chen, Lauren V Collen, Craig Mowat, Kim L. Isaacs, Siddharth Singh, Sunanda V. Kane, Edward V. Loftus, Francis A. Farraye, Scott Snapper, Hani Jneid, Carl J Lavie, Chayakrit Krittanawong Tags: Clinical Research Study Source Type: research
Identification of healthspan-promoting genes in Caenorhabditis elegans based on a human GWAS study
Biogerontology. 2022 Jun 24. doi: 10.1007/s10522-022-09969-8. Online ahead of print.ABSTRACTTo find drivers of healthy ageing, a genome-wide association study (GWAS) was performed in healthy and unhealthy older individuals. Healthy individuals were defined as free from cardiovascular disease, stroke, heart failure, major adverse cardiovascular event, diabetes, dementia, cancer, chronic obstructive pulmonary disease (COPD), asthma, rheumatism, Crohn's disease, malabsorption or kidney disease. Six single nucleotide polymorphisms (SNPs) with unknown function associated with ten human genes were identified as candidate healths...
Source: Biogerontology - June 24, 2022 Category: Geriatrics Authors: Nadine Saul Ineke Dhondt Mikko Kuokkanen Markus Perola Clara Verschuuren Brecht Wouters Henrik von Chrzanowski Winnok H De Vos Liesbet Temmerman Walter Luyten Aleksandra Ze čić Tim Loier Christian Schmitz-Linneweber Bart P Braeckman Source Type: research
Prevalence and Predictors of Stroke in Patients with Crohn's Disease: A Nationwide Study
CONCLUSION: A subset of traditional stroke risk factors are associated with IS in patients with CD. CD patients with these conditions could be targeted for vascular risk reduction and surveillance.PMID:34923435 | DOI:10.1016/j.jstrokecerebrovasdis.2021.106258
Source: Atherosclerosis - December 19, 2021 Category: Cardiology Authors: Satvir Saggi Alain Lekoubou Bruce Ovbiagele Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks)
CONCLUSION: The use of N-acetylcysteine should be considered in a number of conditions as our population ages and levels of glutathione drop. Supplementation may contribute to reducing morbidity and mortality in some chronic conditions as outlined in the article.PMID:34221501 | PMC:PMC8211525 | DOI:10.1155/2021/9949453
Source: Journal of Nutrition and Metabolism - July 5, 2021 Category: Nutrition Authors: Gerry K Schwalfenberg Source Type: research
